Physician profile
Muhammad Khalil
NPI 1184038598
$2,011.45
in general payments reported to CMS, 2019-2025
32 companies · $546 in 2025
The $546 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.39 · 2021: $96.08 · 2023: $295 · 2024: $996 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.93 |
| Education | $310.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $381.31 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, I-Stat |
| Astrazeneca Pharmaceuticals Lp | $133.91 | 2019-2025 | Calquence, Imfinzi |
| Sirtex Medical INC | $133.34 | 2024 | Sir-Spheres Microspheres |
| Celgene Corporation | $119.33 | 2024-2025 | Reblozyl, Pomalyst, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $115.73 | 2024-2025 | Reblozyl, Opdivo |
| Daiichi Sankyo INC. | $99.80 | 2024-2025 | Enhertu |
| Epizyme, INC. | $96.08 | 2021 | |
| Glaxosmithkline, LLC. | $95.68 | 2024-2025 | Ojjaara |
| Abbvie INC. | $87.43 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $83.07 | 2024 | Libtayo |
| Recordati_rare_diseases_inc. | $71.31 | 2024 | Sylvant |
| Rigel Pharmaceuticals, INC. | $51.46 | 2024 | Rezlidhia, Tavalisse |
| Genzyme Corporation | $46.98 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $44.16 | 2024-2025 | Qinlock, Romvimza |
| Coherus Oncology, INC. | $42.27 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $42.22 | 2023-2025 | Pemazyre, Jakafi |
| Stemline Therapeutics INC. | $37.01 | 2024-2025 | Orserdu |
| Puma Biotechnology, INC. | $34.34 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $33.81 | 2024 | |
| Jazz Pharmaceuticals INC. | $28.09 | 2025 | |
| Merck Sharp & Dohme LLC | $27.06 | 2025 | Keytruda |
| Beone Medicines USA, INC. | $25.89 | 2025 | Tevimbra |
| Emd Serono, INC. | $21.59 | 2025 | |
| Eisai INC. | $21.01 | 2025 | |
| Janssen Biotech, INC. | $20.64 | 2024 | Akeega, Erleada |
| Astellas Pharma US INC | $20.04 | 2025 | Xtandi |
| Azurity Pharmaceuticals, INC. | $19.74 | 2025 | Danziten |
| Novocure INC. | $18.52 | 2024 | Optune |
| Sumitomo Pharma America, INC. | $17.11 | 2023 | Orgovyx |
| Tactile Systems Technology INC | $16.75 | 2024 | Flexitouch Plus, Entre Plus |
| Spectrum Pharmaceuticals INC. | $14.62 | 2025 | Rolvedon |
| Pharmaand Gmbh | $11.15 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.